Clodoxopone (LR 19731) is a hypoglycemic agent, developed in the 1980s by Italian company Lusofarmaco. In animal models, the drug lowered the plasma cholesterol and triglyceride levels in several experimental conditions after single or repeated treatments. Results of the clinical trials of the drug are not reported.

Farglitazar is a non-thiazolidinedione insulin sensitizer and agonist of peroxisome proliferator-activated receptor-gamma. GlaxoSmithKline was developing farglitazar for the treatment of liver fibrosis and Type 2 diabetes mellitus.

Evernimicin (SCH 27899) is an oligosaccharide antibiotic. It nteracts with the large ribosomal subunit (50S) and inhibits bacterial protein synthesis. Evernimicin exerts activity against a wide spectrum of gram-positive bacteria and activity against some gram-negative bacteria. Evernimicin was being studied for the treatment of susceptible bacterial infections however its development has been discontinued.

Cinoxolone is a derivative of glycyrrhetinic acid. Is is claimed to possess antiulcer properties.

Metoxepin was developed as an antiemetic, neuroleptic and antihistamine agent. This drug has never been marketed.

Mofegiline (MDL 72,974A or (E)-2-(4-fluorophenethyl)-3-fluoroallylamine, hydrochloride), is a selective and irreversible inhibitor of monoamine oxidase type B (MAO-B) both in vitro and in vivo. In addition, mofegiline inhibits semicarbazide-sensitive amine oxidase activity from human serum and saphenous vein. In phase II studies, MDL 72,974A is proving to be a useful adjunct to conventional therapy of Parkinson's disease. It seems mofegiline development was discontinued.

Resorantel (HOE 296V) is an anthelmintic agent. Resorantel was found to be highly effective against Houttuynia struthionis (a tapeworm, parasite of the small intestine) in ostriches. Resorantel also showed anthelmintic efficacy against Thysaniezia giardi and Avitellina spp. (both tapeworms) when tested in sheep. Similar results have been found in goats and cattle.

Omonasteine was used in sequential peptide ligation for the synthesis of the BRD7 bromodomain.

Cefedrolor is a broad-spectrum cephalexin antibiotic patented by pharmaceutical company Bristol-Myers Co.